Advertisement

Xenotransplantation of the Lung

  • R. N. PersonIII

Abstract

Lung and heart-lung transplantation are now established as therapeutic interventions for many terminal conditions affecting the pulmonary system. Paradoxically, our increasing clinical success exacerbates the donor organ shortage by broadening indications for transplantation and increasing referrals of appropriate patients at an earlier stage in their disease. The most acute need is among patients with either congenital heart disease or cystic fibrosis, for whom heart-lung or double lung transplantation is at present the only viable option. Appropriate organs are often not available for this group of generally young patients; many of those listed for transplant die waiting[1]. Additional patients with other end-stage pulmonary disorders might benefit if more lungs were available.

Keywords

Complement Activation Capillary Leak Hyperacute Rejection High Pulmonary Vascular Resistance Cobra Venom Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cooper DKC. UNDS Registry Statistics In: Cooper DKC. Kemp H, Reemtsma K, White DJG. editors. Xenotransplantation. Heidelberg: Springer-Verlag; 1991.Google Scholar
  2. 2.
    Auchineloss H Jr. Xenogeneic transplantation: a review. Transplantalion. 1986:46:1.CrossRefGoogle Scholar
  3. 3.
    Campbell GS, Crisp NW, Brown EB. Total cardiac by-pass in humans utilizing a pump and heterologous lung oxygenator (dog lungs). Surgery. 1956;40:364.PubMedGoogle Scholar
  4. 4.
    Waldhausen JA, Webb RC, Spencer FC, Bahnson HT. Study of the canine lung as an nxygenator of human and canine blood in exlracorporeal circulation. Surgery. 1957;42:726.PubMedGoogle Scholar
  5. 5.
    Bryant LR, Eiscman B, Avery M. Studies of the porcine lung as an oxygenator for human blood. J Thorac Cardiovasc Surg. 1968;55:255.Google Scholar
  6. 6.
    Halmagyi DFJ, Starzecki B. McRac J, Homer GJ. The lung as the main target organ in the acute phase of transfusion reaction in sheep. J Surg Res. 1963;3:418.PubMedCrossRefGoogle Scholar
  7. 7.
    Morel DR, Gysin I, Pittet JF, Costubella PMM. Role of thromboxane A2 during incompatible homologous and heterologous blood transfusion in sheep. Anesthesiology. 1988;69:A122.CrossRefGoogle Scholar
  8. 8.
    Cook WA, Klausner SK, Sinha S, Kikkawa Y, Veith FJ. A new look at hyperacute rejection. Ann Thorac Surg. 1972;13:388.PubMedCrossRefGoogle Scholar
  9. 9.
    Tavakoli R, Devaux JY, Nonnenmacher L et al. Discordant lung xenograft rejection in the rat. Transplantation. 1992;53:235.PubMedGoogle Scholar
  10. 10.
    Kusajima K, Wax SD, Webb WR, Aust JC. Cinemicroscopy of hyperacute pulmonary rejection. Ann Thorac Surg. 1976;21:341.PubMedCrossRefGoogle Scholar
  11. 11.
    Kusajima K, Aust JC, Wax SD. Webb WR. Hemodynamic and functional changes in xenogenic, perfused, isolated lungs. J Thorac Cardiovasc Surg. 1976;72:115.PubMedGoogle Scholar
  12. 12.
    Veith FJ, Richards KU, Hagstrom JWC. Montefusco CM. Intrafamilial lung xenografts from fox to dog. J Thorac Cardiovasc Surg. 1981;81:546.PubMedGoogle Scholar
  13. 13.
    Speiller PB, Kikkawa Y, Veith FJ, Cook WA. Steroid protection of a pulmonary xenograft model. Surg Forum. 1972;23:272.PubMedGoogle Scholar
  14. 14.
    Pierson RN III. Tew DN, Konig WK et al. Pig lungs are susceptible to hyperacute rejection by human blood in a working ex vivo heart-lung model. Transplant Proc. 1994;26:1318.PubMedGoogle Scholar
  15. 15.
    Pierson RN III, Dunning JJ, Konig WK et al. Mechanisms governing the pace and character of pig heart and lung rejection by human blood. Transplant Proc. 1994;26:2337.PubMedGoogle Scholar
  16. 16.
    Fischel RJ, Dalmasso AP, Vercellotti GM et al. Mechanism of complement activation in the hyperacute rejection of porcine organs iransplanted into primate recipients. Am J Pathol. 1992;140:1157.PubMedGoogle Scholar
  17. 17.
    Fukushima N, Bouchart F, Gundry SR et al. The role of anti-pig antibody in pig-tobaboon cardiac xenotransplant rejection. Transplantalion. 1994;57:923.CrossRefGoogle Scholar
  18. 18.
    Kirk AD, Heinle JS, Mault JR. Santilippo F. Ex vivo characterization of human anti-porcine hyperacute cardiac rejection. Transplantation. 1993;56:785.PubMedCrossRefGoogle Scholar
  19. 19.
    Young VK, Pierson RN III, Kaspar-Konig W et al. Pig hearts transgenic for human decay accelerating factor are protected from hyperacute rejection. Submitted for publication.Google Scholar
  20. 20.
    McCurry KR, Kooyman D, Diamond L et al. Human complement regulatory proteins in transgenic animals regulate complement activation in xenoperfused organs. Presented to the Transplantation Society. Kyoto.Google Scholar
  21. 21.
    Pierson RN III, Young VK, Kaspar-Konig W, While DJG, Wallwork J. Expression of human complement regulatory protein may protect pig lung against hyperacute rejection by human blood. J Heart Lung Transplant. Presented to the International Society for Heart and Lung Transplantation. San Francisco. 1995 (in press)Google Scholar
  22. 22.
    Pruitt SK, Kirk AD, Bollinger RR et al. The effect of soluble complement receptor type I on hyperacute rejection of porcine xenografts. Transplantation. 1994;57:363.PubMedCrossRefGoogle Scholar
  23. 23.
    Cooper DKC, Human PA, Lexer G et al. Effect of cyclosporin and antibody absorption on survival of pig hearts in baboons. J Heart Transplant. 1988;7:238.PubMedGoogle Scholar
  24. 24.
    Kaplon RJ, Platt JL, Kwiatkowski PA. Absence of hyperacute rejection in pig-to-primate orthotopic pulmonary xenografts. Transplantation. 1995;59410.Google Scholar
  25. 25.
    Shah AS, O’Hair DP, Kaplon RJ et al. Absence of hyperacute rejection in pig-to-primate double lung xenografts. Presented to the International Society for Heart and Lung Transplantation. San Francisco. 1995.Google Scholar
  26. 26.
    Pierson RN III. Kaspar-Konig W, Tew DN et al. Hyperacute rejection in a pig-to-human lung transplant model. I. The role of antipig antibody and complement. Submitted for publication.Google Scholar
  27. 27.
    Pierson RN III, Tew DF, Konig WK, White DJG, Wallwork J. Profound pulmonary hypertension, characteristic of pig lung rejection by human blood, is mediated by xenoreactive antibody independent of complement. Transplant Proc. 1995;27:274.PubMedGoogle Scholar
  28. 28.
    Mulligan MS, Paulson JC. De Frees S et al. Protective effects of oligosaccharides in P-sclectin-dependent lung injury. Nature. 1993;364:149.PubMedCrossRefGoogle Scholar
  29. 29.
    Colletti LM, Burtch GD, Remick DG et al. The production of tumor necrosis factor alpha and the development of a pulmonary capillary injury following hepatic ischemia/reperfusion. Transplantation. 1990;49:268.PubMedCrossRefGoogle Scholar
  30. 30.
    Wheeler AP, Jesmok G, Brigham KL. Tumor necrosis factor’s effects on lung mechanics, gas exchange, and airway reactivity in sheep. Am J Physiol. 1990;161:2542.Google Scholar
  31. 31.
    Bando K, Pillai R, Cameron DK et al. Leukocyte depletion ameliorates free radical-mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990;99:873.PubMedGoogle Scholar
  32. 32.
    Duke SS, Guerry-Forec ML, Forbes JT et al. Acute endotoxin-induced lymphocyte subset sequestration in sheep lungs. Lab Invest. 1990;62:355.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • R. N. PersonIII

There are no affiliations available

Personalised recommendations